EBMT 2017

3:26
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau
6:43
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister
2:40
Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly
2:36
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben
3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau
1:50
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial
2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon
1:52
Improving the outcomes of transplantation with bispecific antibodies
Hermann Einsele
1:50
Can transplant quality be improved by training medical personnel?
Riccardo Saccardi
4:44
What are the advantages of multiple myeloma maintenance therapy?
Laurent Garderet
1:29
Vaccination after stem cell transplant – why and when?
Hermann Einsele
2:03
Pharmacoeconomics of mobilization
Christian Chabannon
1:28
Bettering transplant outcomes by optimizing stem cell mobilization
Riccardo Saccardi
2:25
New insight into the biology of multiple myeloma: from clonal evolution to new treatment options
Nikhil Munshi
2:28
Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
Nicolaus Kröger
5:44
How can social media bring together doctors and patients?
Naveen Pemmaraju
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals